Glucose Pattern in Infertile Women Receiving Assisted Reproduction Using Continuous Glucose Monitoring
Launched by SHANGHAI 6TH PEOPLE'S HOSPITAL · Mar 6, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how glucose levels change in women who are undergoing assisted reproduction treatments, like in vitro fertilization (IVF). Researchers want to see if these changes in glucose levels, which will be monitored continuously, have any impact on the success of the treatments. This is important because understanding glucose patterns could help improve outcomes for women trying to conceive.
To participate in this study, women must be between 18 and 40 years old and planning to start their first or second IVF cycle at the study center. They should be willing to provide consent and have specific health conditions that don’t interfere with the study. Participants will wear a small device that continuously tracks their glucose levels during treatment. It's important to note that certain medical conditions or recent treatments may prevent someone from joining the study. This trial aims to provide valuable insights that might help others in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Informed consent and voluntary participation in this study;
- • 2. Age ≥ 18 years and ≤40 years old;
- • 3. Infertile patients who will undergo their first or second cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the study center;
- • 4. The chosen ovulation promotion regimens is the GnRH antagonist regimen/progesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.
- Exclusion Criteria:
- • 1. Recent infections (excluding viral infections of the reproductive system such as HPV);
- • 2. Recent glucocorticoid treatment or chemotherapy;
- • 3. Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;
- • 4. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.
About Shanghai 6th People's Hospital
Shanghai 6th People's Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital focuses on a wide range of therapeutic areas, striving to enhance patient outcomes and contribute to medical knowledge. With a dedicated team of experienced researchers and clinicians, Shanghai 6th People's Hospital emphasizes rigorous scientific methodology and ethical standards, ensuring that all trials are conducted with the utmost integrity and patient safety in mind. Through collaboration with various stakeholders, the hospital aims to bridge the gap between clinical research and real-world application, ultimately improving healthcare delivery both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported